Marker Therapeutics, Inc.

MRKR
$1.32 (+ $0.01 + 0.38%)
Last updated: 2026-06-26 23:43 UTC
MRKR Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS57055L1070
CUSIP57055L107
Market Price1.32
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.17
Market Cap$23.2M
Book Value1.1
Price to Book1.26
Beta1.35
52w High4.07
52w Low0.81
Next Earnings DateN/A

Marker Therapeutics, Inc. trades under ticker MRKR on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US57055L1070, CUSIP 57055L107.

About the Company
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Price History